# Statins: Overview

Source page: https://www.materialinsights.org/technologies/statins/tech-overview/

#### What it does

The job the technology does for people, in a short paragraph

Statins lower the LDL cholesterol in the blood that builds up in artery walls, and so cut heart attacks and strokes ^[1]. Across 14 trials they reduced heart attacks by 25 to 30% ^[1]. The first was approved in 1987 ^[1]. In 41 low- and middle-income countries, about 8% of eligible adults used one for primary prevention in surveys from 2013 to 2019 ^[4].

as of 2026-11-11

#### How it works

The working principle in plain words, step by step

The body gets cholesterol from food and makes much of its own, mostly in the liver ^[1, 2]. One step on that production line is run by an enzyme, HMG-CoA reductase, which turns a molecule called HMG-CoA into mevalonate ^[3]. A statin molecule fits the enzyme and blocks it, so the liver makes less cholesterol ^[3]. Short of cholesterol, liver cells put more LDL receptors on their surface ^[2, 3]. These receptors catch LDL particles, the main carriers of cholesterol in the blood, and pull them into the cell ^[2]. The level of LDL in the blood falls, and less of it is left to form the fatty deposits that narrow blood vessels ^[1].

as of 2026-11-11

#### Key figures

The handful of numbers that size it up, each with its unit, year and source

| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Fall in LDL cholesterol with simvastatin in the 4S trial | 35 | % | 1994 | ^[1] |
| Fall in coronary heart disease deaths in the 4S trial | 40 | % | 1994 | ^[1] |
| Statin use for primary prevention among eligible adults in 41 low- and middle-income countries | 8 | % | 2019 | ^[4] |
| Statin use for secondary prevention in the same countries | 21.9 | % | 2019 | ^[4] |
| LDL cholesterol lowering with high-intensity statin treatment (more than) | 50 | % | 2024 | ^[3] |

as of 2026-11-11. The 41-country figures come from surveys carried out between 2013 and 2019 [4]; the year shown is the end of that period. The 4S rows carry 1994, the year the trial results were reported [1]. The high-intensity row carries 2024, the update year of source 3, a publication year, not a data year.

#### Where it is used

The main places and products the technology is found in

- Prevention of heart attacks and strokes in people at high risk (primary prevention)
- Treatment after a heart attack or stroke to prevent another (secondary prevention)
- Inherited high cholesterol
- Prescribed in general practice and hospital clinics, taken as daily tablets

as of 2026-11-11

#### Scale today

How much of it there is now: units in use, made each year and who uses it

**Users**
: An estimated 30 million people worldwide ^[1, 6]; no newer world count was found

**Unit**
: people taking statins

**Year**
: 2008

**Note**
: The 30 million figure appears in the 2008 Lasker award text and again in Endo's 2010 review; 2008 is a publication year, not a data year. Use in poorer countries remains low, about 8% of eligible adults for prevention ^[4].

as of 2026-11-11

#### Sources

1. [Statins for lowering LDL and decreasing heart attacks](https://laskerfoundation.org/winners/statins-for-lowering-ldl-and-decreasing-heart-attacks/) Lasker Foundation (text of the 2008 Lasker-DeBakey Clinical Medical Research Award to Akira Endo), 2008
2. [The Nobel Prize in Physiology or Medicine 1985 - Press release](https://www.nobelprize.org/nobel_prizes/medicine/laureates/1985/press.html) Nobel Assembly at Karolinska Institutet, 1985
3. [Statin Medications](https://www.statpearls.com/point-of-care/29463) StatPearls (NCBI Bookshelf), last updated 29 February 2024, 2024
4. [Use of statins for the prevention of cardiovascular disease in 41 low- and middle-income countries: a cross-sectional study of nationally representative, individual-level data](https://research.birmingham.ac.uk/en/publications/use-of-statins-for-the-prevention-of-cardiovascular-disease-in-41/) The Lancet Global Health 10(3):e369-e379 (Marcus and others), record at the University of Birmingham, 2022
5. [A historical perspective on the discovery of statins](https://pmc.ncbi.nlm.nih.gov/articles/PMC3108295/) Proceedings of the Japan Academy, Series B 86(5):484-493 (Akira Endo), on PubMed Central, 2010

## Other sections

- [Summary](https://www.materialinsights.org/technologies/statins/index.md)
- [Science](https://www.materialinsights.org/technologies/statins/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/statins/tech-evolution/index.md)
- [Materials](https://www.materialinsights.org/technologies/statins/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/statins/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/statins/tech-industries/index.md)
